Takeda Pharmaceutica

4502
End-of-day quote Tokyo - 06/21
3778JPY
-1.18%
Prev.3823.0000
Open3832.0000
High3839.0000
Low3753.0000
Volume6 996 600
Financials
Sales 2020 3 361 B
EBIT 2020 379 B
R. net 2020 -213 802 M
Debt 2020 4 513 B
Rend. 2020 4,76%
P/E ratio 2020 -
P/E ratio 2021 32,57
EV / Sales 2020 3,11x
EV / Sales 2021 2,92x
Capitalization 5 955 B
Company
Takeda Pharmaceutical Company specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. Net sales break down by activity as follows:
- sale of drugs (95.5%);
- sale of...
Sector :
Pharmaceuticals - NEC
Calendar :
2019-06-27 Shareholder meeting
Trading Rating :
Investor Rating :
Latest news
10:59aTAKEDA PHARMACEUTICAL : Informa Pharma Intelligence Wins Two SIPAwards at 40th Annual Conference for Editorial Content
AQ
06/11TAKEDA PHARMACEUTICAL : Amyloidosis treatment discontinued from clinical trials
AQ
06/09TAKEDA PHARMACEUTICAL : Provides Update on TOURMALINE-AL1 Phase 3 Trial in AL Amyloidosis
AQ
06/07TAKEDA PHARMACEUTICAL : ditches late-stage Ninlaro trial
AQ
06/05TAKEDA PHARMACEUTICAL : Provides Update on TOURMALINE-AL1 Phase 3 Trial in AL Amyloidosis
BU
06/04TAKEDA PHARMACEUTICAL : Presents Results from Lung Portfolio Including Phase 1/2 Study of TAK-788 in a Rare Form of NSCLC and New Data on Overall Health-Related Quality of Life for ALUNBRIG
AQ
06/04TAKEDA PHARMACEUTICAL : New Ad-hoc Analysis of Phase 3 HELP Study Evaluates Prevention of HAE Attacks with TAKHZYRO during Early Treatment Phase
AQ
06/03TAKEDA PHARMACEUTICAL : Presents Results from Lung Portfolio
PU
Technical analysis trends
Short TermMid-TermLong Term
TrendBearishBearishBearish
Resistance3 9494 0594 291
Spread/Res.-4,3%-6,9%-12%
Spread/Supp.5,8%5,8%3,0%
Support3 5723 5723 669